Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations

Poly ADP-ribose polymerase inhibitor (PARPi) has become an important maintenance therapy for ovarian cancer after surgery and cytotoxic chemotherapy, which has changed the disease management model of ovarian cancer, greatly decreased the risk of recurrence, and made the prognosis of ovarian cancer b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qin Xu, Zhengyu Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	poly ADP-ribose polymerase inhibitors homologous recombination deficiency ovarian cancer combination therapy HRD status detection Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/adeb1491c1634704849a192d2caa2986
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:adeb1491c1634704849a192d2caa2986
record_format	dspace
spelling	oai:doaj.org-article:adeb1491c1634704849a192d2caa29862021-12-01T13:47:41ZUpdate on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations1663-981210.3389/fphar.2021.743073https://doaj.org/article/adeb1491c1634704849a192d2caa29862021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.743073/fullhttps://doaj.org/toc/1663-9812Poly ADP-ribose polymerase inhibitor (PARPi) has become an important maintenance therapy for ovarian cancer after surgery and cytotoxic chemotherapy, which has changed the disease management model of ovarian cancer, greatly decreased the risk of recurrence, and made the prognosis of ovarian cancer better to certain extent. The three PARPis currently approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of ovarian cancer are Olaparib, Niraparib and Rucaparib. With the incremental results from new clinical trials, the applicable population of PARPi for ovarian cancer have expanded to population with non-BRCA mutations. Although BRCA mutated population are still the main beneficiaries of PARPi, recent clinical trials indicated PARPis’ therapeutic potential in non-BRCA mutated population, especially in homologous recombination repair deficiency (HRD) positive population. However, lack of unified HRD status detection method poses a challenge for the accurate selection of PARPi beneficiaries. The reversal of homologous recombination (HR) function during the treatment will not only cause resistance to PARPis, but also reduce the accuracy of the current method to determine HRD status. Therefore, the development of reliable HRD status detection methods to determine the beneficiary population, as well as rational combination treatment are warranted. This review mainly summarizes the latest clinical trial results and combination treatment of PARPis in ovarian cancer with non-BRCA mutations, and discusses the application prospects, including optimizing combination therapy against drug resistance, developing unified and accurate HRD status detection methods for patient selection and stratification. This review further poses an interesting topic: the efficacy and safety in patients retreated with PARPis after previous PARPi treatment---“PARPi after PARPi”.Qin XuZhengyu LiFrontiers Media S.A.articlepoly ADP-ribose polymerase inhibitorshomologous recombination deficiencyovarian cancercombination therapyHRD status detectionTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	poly ADP-ribose polymerase inhibitors homologous recombination deficiency ovarian cancer combination therapy HRD status detection Therapeutics. Pharmacology RM1-950
spellingShingle	poly ADP-ribose polymerase inhibitors homologous recombination deficiency ovarian cancer combination therapy HRD status detection Therapeutics. Pharmacology RM1-950 Qin Xu Zhengyu Li Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
description	Poly ADP-ribose polymerase inhibitor (PARPi) has become an important maintenance therapy for ovarian cancer after surgery and cytotoxic chemotherapy, which has changed the disease management model of ovarian cancer, greatly decreased the risk of recurrence, and made the prognosis of ovarian cancer better to certain extent. The three PARPis currently approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of ovarian cancer are Olaparib, Niraparib and Rucaparib. With the incremental results from new clinical trials, the applicable population of PARPi for ovarian cancer have expanded to population with non-BRCA mutations. Although BRCA mutated population are still the main beneficiaries of PARPi, recent clinical trials indicated PARPis’ therapeutic potential in non-BRCA mutated population, especially in homologous recombination repair deficiency (HRD) positive population. However, lack of unified HRD status detection method poses a challenge for the accurate selection of PARPi beneficiaries. The reversal of homologous recombination (HR) function during the treatment will not only cause resistance to PARPis, but also reduce the accuracy of the current method to determine HRD status. Therefore, the development of reliable HRD status detection methods to determine the beneficiary population, as well as rational combination treatment are warranted. This review mainly summarizes the latest clinical trial results and combination treatment of PARPis in ovarian cancer with non-BRCA mutations, and discusses the application prospects, including optimizing combination therapy against drug resistance, developing unified and accurate HRD status detection methods for patient selection and stratification. This review further poses an interesting topic: the efficacy and safety in patients retreated with PARPis after previous PARPi treatment---“PARPi after PARPi”.
format	article
author	Qin Xu Zhengyu Li
author_facet	Qin Xu Zhengyu Li
author_sort	Qin Xu
title	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
title_short	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
title_full	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
title_fullStr	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
title_full_unstemmed	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
title_sort	update on poly adp-ribose polymerase inhibitors in ovarian cancer with non-brca mutations
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/adeb1491c1634704849a192d2caa2986
work_keys_str_mv	AT qinxu updateonpolyadpribosepolymeraseinhibitorsinovariancancerwithnonbrcamutations AT zhengyuli updateonpolyadpribosepolymeraseinhibitorsinovariancancerwithnonbrcamutations
_version_	1718405132986613760

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations

Ejemplares similares